Eli Lilly acquires biotech firm in new insulin venture

A new form of insulin drugs at Protomer Technoloigies caught the eye of Eli Lilly, which has bought the firm for a sum that could surpass USD 1bn (DKK 6.3bn).
Photo: Mike Blake/REUTERS / X00030
Photo: Mike Blake/REUTERS / X00030

US pharmaceutical company Eli Lilly has entered into an agreement to acquire biotech company Protomer Technologies for a price that could total more than USD 1bn. The final figure will be dependent on future performance and milestone payments.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading